The market, built from the bottom up

A share of the eligible population, not a share of the market.

333,830 New United States prostate cancer diagnoses in 2026

~26,700 Diagnosed at distant stage, being eight per cent of new cases

~89,000 Annual incident metastatic pool. The CDC finds seventy per cent of men with metastatic disease were first diagnosed localised

~71,000 PSMA positive, the biomarker being present in more than eighty per cent of prostate cancer patients

<5% The share of that eligible pool Aletheia treats at full build

Sources: American Cancer Society, Cancer Statistics 2026; Centers for Disease Control and Prevention analysis of metastatic prostate cancer; Novartis media release, 31 July 2026. This plan does not require winning the market. It requires a small share of a market whose binding constraint is licensed sites rather than eligible patients.